Edesa Biotech is trading at $2.74, with a +6.88% change; the cause of its October 28 after-hours move remains unclear. - No confirmed new company announcement or reliable report explains the move. - The October 15 FDA clearance for a Phase 2 vitiligo study is earlier context, not a confirmed fresh catalyst. - Major indices were mixed, and available evidence does not establish a broader-market explanation. The after-hours quote is based on the provided price context.